{
  "first_published_at": "2012-06-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON155759", 
  "title": "Tacrolimus ointment (Protopic): reminder of a possible risk of malignancies including lymphomas and skin cancers", 
  "tags": "{\"parsed_therapeutic\": [\"dermatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Dermatology\"]}", 
  "_document_number": 109, 
  "label": "Reminder", 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "dermatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Tacrolimus ointment (Protopic): reminder of a possible risk of malignancies including lymphomas and skin cancers</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Healthcare professionals are reminded that topically applied tacrolimus (Protopic) may be associated with a possible increased risk of malignancy. Protopic must not be used in patients aged younger than 2 years, and only the lower strength 0.03% version may be used in children aged 2 - 16 years.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Tacrolimus ointment (Protopic) is used to treat moderate to severe atopic dermatitis flares, and to maintain flare-free intervals, in adults and adolescents age 16 years and older, who do not respond to, or are intolerant of, conventional therapies such as topical corticosteroids.</p>\n\n<p>Protopic is available in two strengths containing tacrolimus 0.03% and 0.1%, respectively. The lower strength ointment can be used to treat moderate to severe atopic dermatitis in children of 2 years and above, as well as adults and adolescents. The higher strength ointment is licensed only for use in patients aged 16 years and older.</p>\n\n<h3><strong>Risk of malignancies</strong></h3>\n\n<p>Healthcare professionals are reminded that tacrolimus may be associated with a possible risk of malignancy. Benign as well as malignant neoplasms including Epstein-Barr virus-associated lymphoproliferative disorders and skin malignancies have been reported in association with oral (systemic) tacrolimus treatment.</p>\n\n<p>Cases of malignancies, including lymphomas and skin cancers have also been reported in patients using topically applied tacrolimus since it was licensed in 1999. In addition, findings from epidemiological studies have suggested a possible increased risk of cutaneous T-cell lymphoma in patients treated with topical calcineurin inhibitors, including tacrolimus ointment<cite>Hui RL et al. Ann Pharmacother 2009; 43 (12):1956-1963</cite> <cite>Schneeweiss S et al. Dermatology 2009; 219(1): 7-21</cite> <cite>Arana A et al. Presentation at the annual meeting of the International Society for Pharmacoepidemiology, Brighton, UK 2010</cite>.</p>\n\n<p>Healthcare professionals must remember that Protopic should not be prescribed to patients younger than 2 years, and that the use of Protopic in children aged 2 &#8211; 16 years is restricted to the lower strength 0.03% ointment only.</p>\n\n<p>In addition, Protopic should not be applied to lesions that are considered to be potentially malignant or pre-malignant, or used in patients with congenital or acquired immunodeficiencies, or in patients on therapy that causes immunosuppression.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832\">Letter to health professionals sent in May 2012</a></p>\n\n<p>BNF section 13.5.3: <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/119636.htm\">Drugs affecting the immune response</a></p>\n\n<p><em>Article citation: Drug Safety Update June 2012, vol 5 issue 11: S1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Tacrolimus ointment (Protopic) is used to treat moderate to severe atopic dermatitis flares, and to maintain flare-free intervals, in adults and adolescents age 16 years and older, who do not respond to, or are intolerant of, conventional therapies such as topical corticosteroids.</p>\n\n<p>Protopic is available in two strengths containing tacrolimus 0.03% and 0.1%, respectively. The lower strength ointment can be used to treat moderate to severe atopic dermatitis in children of 2 years and above, as well as adults and adolescents. The higher strength ointment is licensed only for use in patients aged 16 years and older.</p>\n\n<h3><strong>Risk of malignancies</strong></h3>\n\n<p>Healthcare professionals are reminded that tacrolimus may be associated with a possible risk of malignancy. Benign as well as malignant neoplasms including Epstein-Barr virus-associated lymphoproliferative disorders and skin malignancies have been reported in association with oral (systemic) tacrolimus treatment.</p>\n\n<p>Cases of malignancies, including lymphomas and skin cancers have also been reported in patients using topically applied tacrolimus since it was licensed in 1999. In addition, findings from epidemiological studies have suggested a possible increased risk of cutaneous T-cell lymphoma in patients treated with topical calcineurin inhibitors, including tacrolimus ointment<cite>Hui RL et al. Ann Pharmacother 2009; 43 (12):1956-1963</cite> <cite>Schneeweiss S et al. Dermatology 2009; 219(1): 7-21</cite> <cite>Arana A et al. Presentation at the annual meeting of the International Society for Pharmacoepidemiology, Brighton, UK 2010</cite>.</p>\n\n<p>Healthcare professionals must remember that Protopic should not be prescribed to patients younger than 2 years, and that the use of Protopic in children aged 2 &#8211; 16 years is restricted to the lower strength 0.03% ointment only.</p>\n\n<p>In addition, Protopic should not be applied to lesions that are considered to be potentially malignant or pre-malignant, or used in patients with congenital or acquired immunodeficiencies, or in patients on therapy that causes immunosuppression.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832\">Letter to health professionals sent in May 2012</a></p>\n\n<p>BNF section 13.5.3: <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/119636.htm\">Drugs affecting the immune response</a></p>\n\n<p><em>Article citation: Drug Safety Update June 2012, vol 5 issue 11: S1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-06-01", 
  "date_last_modified": "2012-06-21", 
  "_assets": [], 
  "_item_id": 109, 
  "summary": "", 
  "body": "Article date: June 2012\n\nTacrolimus ointment (Protopic) is used to treat moderate to severe atopic dermatitis flares, and to maintain flare-free intervals, in adults and adolescents age 16 years and older, who do not respond to, or are intolerant of, conventional therapies such as topical corticosteroids.\n\nProtopic is available in two strengths containing tacrolimus 0.03% and 0.1%, respectively. The lower strength ointment can be used to treat moderate to severe atopic dermatitis in children of 2 years and above, as well as adults and adolescents. The higher strength ointment is licensed only for use in patients aged 16 years and older.\n\n### Risk of malignancies\n\nHealthcare professionals are reminded that tacrolimus may be associated with a possible risk of malignancy. Benign as well as malignant neoplasms including Epstein-Barr virus-associated lymphoproliferative disorders and skin malignancies have been reported in association with oral (systemic) tacrolimus treatment.\n\nCases of malignancies, including lymphomas and skin cancers have also been reported in patients using topically applied tacrolimus since it was licensed in 1999. In addition, findings from epidemiological studies have suggested a possible increased risk of cutaneous T-cell lymphoma in patients treated with topical calcineurin inhibitors, including tacrolimus ointment[^1] [^2] [^3]. \n\nHealthcare professionals must remember that Protopic should not be prescribed to patients younger than 2 years, and that the use of Protopic in children aged 2 â€“ 16 years is restricted to the lower strength 0.03% ointment only.\n\nIn addition, Protopic should not be applied to lesions that are considered to be potentially malignant or pre-malignant, or used in patients with congenital or acquired immunodeficiencies, or in patients on therapy that causes immunosuppression.\n\nFurther information:\n\n[Letter to health professionals sent in May 2012](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832)\n\nBNF section 13.5.3: [Drugs affecting the immune response](http://www.medicinescomplete.com/mc/bnf/current/119636.htm)\n\nArticle citation: Drug Safety Update June 2012, vol 5 issue 11: S1\n\n[^1]: Hui RL et al. Ann Pharmacother 2009; 43 (12):1956-1963\n\n[^2]: Schneeweiss S et al. Dermatology 2009; 219(1): 7-21\n\n[^3]: Arana A et al. Presentation at the annual meeting of the International Society for Pharmacoepidemiology, Brighton, UK 2010\n"
}